These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451 [TBL] [Abstract][Full Text] [Related]
25. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system. Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071 [TBL] [Abstract][Full Text] [Related]
27. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698 [TBL] [Abstract][Full Text] [Related]
28. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261 [TBL] [Abstract][Full Text] [Related]
29. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Siu A; Virtanen C; Jongstra J Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779 [TBL] [Abstract][Full Text] [Related]
31. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557 [TBL] [Abstract][Full Text] [Related]
32. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411 [TBL] [Abstract][Full Text] [Related]
33. Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053 [TBL] [Abstract][Full Text] [Related]
34. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Warfel NA; Sainz AG; Song JH; Kraft AS Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781 [TBL] [Abstract][Full Text] [Related]
35. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations. Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293 [TBL] [Abstract][Full Text] [Related]
36. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515 [TBL] [Abstract][Full Text] [Related]
37. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes. Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859 [TBL] [Abstract][Full Text] [Related]
38. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999 [TBL] [Abstract][Full Text] [Related]
39. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136 [TBL] [Abstract][Full Text] [Related]
40. Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Le X; Antony R; Razavi P; Treacy DJ; Luo F; Ghandi M; Castel P; Scaltriti M; Baselga J; Garraway LA Cancer Discov; 2016 Oct; 6(10):1134-1147. PubMed ID: 27604488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]